Biocompatibility of basic fibroblast growth factor-poly(lactic-co-glycolic acid) microspheres/ hydroxyapatite/poly(l-lactic acid) porous materialsBiocompatibility of basic fibroblast growth factor-poly(lactic-co-glycolic acid) microspheres/ hydroxyapatite/poly(l-lactic acid) porous materials

doi:10.3969/j.issn.2095-4344.0068

Abstract

Abstract:

BACKGROUND: To date, no single material can completely meet the clinical requirements. However, the composite materials characterized by good biodegradability, biocompatibility and osteoconductivity have become a highlight of the artificial bone materials.

OBJECTIVE: To synthesize the basic fibroblast growth factor (bFGF)-poly(lactic-co-glycolic acid) (PLGA) microspheres/hydroxyapatite (HA)/poly(l-lactic acid) (PLLA) porous bone scaffolds, and to observe the physicochemical properties and biocompatibility of the composite material.

METHODS: The bFGF-PLGA microspheres were prepared by double emulsion method, and then six kinds of materials were made including PLLA, PLLA/HA, PLLA/PLGA, PLLA/HA/PLGA, PLLA/HA/bFGF, and bFGF-PLGA microspheres/PLLA/HA. The characterization of the materials were observed by particle size analyzer, transmission electron microscopy, X-ray diffraction, Fourier transform infrared spectrometer, microcomputer differential thermal balance, and scanning electron microscope. Toxicity of these materials and proliferation of bone marrow mesechymal stem cells seeded onto these materials were analyzed and compared.

RESULTS AND CONCLUSION: The average particle size of bFGF-PLGA microspheres was about 250 nm, the average drug-loading capacity was (26.03±0.17)%, and the entrapment percentage was (90.65±2.68)%. The prepared bFGF-PLGA microspheres were spherical and had good dispersibility. In addition, all the six kinds of materials had a porous structure with similar pore diameter, in which the microspheres and particles exhibited a rational distribution. The toxic level of bFGF-PLGA microspheres/PLLA/HA, bFGF/HA/PLLA and HAP/PLLA was graded as 1 (with a relative survival rate ≥ 80%), indicating no obvious toxicity or slight toxicity. All these six kinds of composite materials can promote the proliferation of bone marrow mesenchymal stem cells, and the bFGF-PLGA microspheres/PLLA/HA shows the best effects on cell proliferation and has good biocompatibility.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Fibroblast Growth Factors, Hydroxyapatites, Biocompatible Materials, Tissue Engineering

CLC Number:

R318

Li Zhi-yue, Zhu Zhi-bo, Zhao Qun, Xiang Si-yu, Zhao Peng, Xu Zhe-wei. Biocompatibility of basic fibroblast growth factor-poly(lactic-co-glycolic acid) microspheres/ hydroxyapatite/poly(l-lactic acid) porous materialsBiocompatibility of basic fibroblast growth factor-poly(lactic-co-glycolic acid) microspheres/ hydroxyapatite/poly(l-lactic acid) porous materials[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(6): 914-920.

Figures/Tables 12

References

[1]Parsons B, Strauss E. Surgical management of chronic osteomyelitis. Am J Surg. 2004;188(1A Suppl):57-66.

[2]Kovacevic D, Fox AJ, Bedi A, et al. Calcium-phosphate matrix with or without TGF-β3 improves tendon-bone healing after rotator cuff repair. Am J Sports Med. 2011;39(4):811-819.

[3]Servin-Trujillo MA, Reyes-Esparza JA, Garrido-Fariña G, et al. Use of a graft of demineralized bone matrix along with TGF-β1 leads to an early bone repair in dogs. J Vet Med Sci. 2011;73(9): 1151-1161.

[4]Bichara DA, O'Sullivan NA, Pomerantseva I, et al. The tissue-engineered auricle: past, present, and future. Tissue Eng Part B Rev. 2012;18(1):51-61.

[5]Eppley BL, Pietrzak WS, Blanton MW. Allograft and alloplastic bone substitutes: a review of science and technology for the craniomaxillofacial surgeon. J Craniofac Surg. 2005;16(6): 981-989.

[6]Goldberg VM. Selection of bone grafts for revision total hip arthroplasty. Clin Orthop Relat Res. 2000;(381):68-76.

[7]Karaoglu S, Baktir A, Kabak S, et al. Experimental repair of segmental bone defects in rabbits by demineralized allograft covered by free autogenous periosteum. Injury. 2002;33(8): 679-683.

[8]Clayer M. Injectable form of calcium sulphate as treatment of aneurysmal bone cysts. ANZ J Surg. 2008;78(5):366-370.

[9]Yang J, Yamato M, Nishida K, et al. Cell delivery in regenerative medicine: the cell sheet engineering approach. J Control Release. 2006;116(2):193-203.

[10]Ouyang HW, Toh SL, Goh J, et al. Assembly of bone marrow stromal cell sheets with knitted poly (L-lactide) scaffold for engineering ligament analogs. J Biomed Mater Res B Appl Biomater. 2005;75(2):264-271.

[11]Castoldi M, Pistone M, Caruso C, et al. Osteoblastic cells from rat long bone. II: Adhesion to substrata and integrin expression in primary and propagated cultures. Cell Biol Int. 1997;21(1):7-16.

[12]Manduca P, Sanguineti C, Pistone M, et al. Differential expression of alkaline phosphatase in clones of human osteoblast-like cells. J Bone Miner Res. 1993;8(3):291-300.

[13]Huibregtse BA, Johnstone B, Goldberg VM, et al. Effect of age and sampling site on the chondro-osteogenic potential of rabbit marrow-derived mesenchymal progenitor cells. J Orthop Res. 2000;18(1):18-24.

[14]Service RF. Tissue engineers build new bone. Science. 2000; 289(5484):1498-1500.

[15]Srouji S, Blumenfeld I, Rachmiel A, et al. Bone defect repair in rat tibia by TGF-beta1 and IGF-1 released from hydrogel scaffold. Cell Tissue Bank. 2004;5(4):223-230.

[16]Schnettler R, Alt V, Dingeldein E, et al. Bone ingrowth in bFGF-coated hydroxyapatite ceramic implants. Biomaterials. 2003;24(25):4603-4608.

[17]Tan HC, Lei J, Jiang DZ. Effect of bFGF on hematopoietic regulation of bone marrow stromal cells. Hunan Yi Ke Da Xue Xue Bao. 2003;28(1):83-84.

[18]Varkey M, Kucharski C, Haque T, et al. In vitro osteogenic response of rat bone marrow cells to bFGF and BMP-2 treatments. Clin Orthop Relat Res. 2006;443:113-123.

[19]Li Y, Chen HQ, Cheng M, et al. Bone marrow stromal cells co-modified with BMP-2 and bFGF gene.Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006;22(2):133-136.

[20]Kilic MA, Ozlu E, Calis S. A novel protein-based anticancer drug encapsulating nanosphere: apoferritin-doxorubicin complex. J Biomed Nanotechnol. 2012;8(3):508-514.

[21]Batheja P, Sheihet L, Kohn J, et al. Topical drug delivery by a polymeric nanosphere gel: Formulation optimization and in vitro and in vivo skin distribution studies. J Control Release. 2011;149(2):159-167.

[22]Estevanato L, Cintra D, Baldini N, et al. Preliminary biocompatibility investigation of magnetic albumin nanosphere designed as a potential versatile drug delivery system. Int J Nanomedicine. 2011;6:1709-1717.

[23]Vukomanovi? M, Skapin SD, Poljanšek I, et al. Poly(D,L-lactide-co-glycolide)/hydroxyapatite core-shell nanosphere. Part 2: Simultaneous release of a drug and a prodrug (clindamycin and clindamycin phosphate). Colloids Surf B Biointerfaces. 2011;82(2):414-421.

[24]Holmes TC. Novel peptide-based biomaterial scaffolds for tissue engineering. Trends Biotechnol. 2002;20(1):16-21.

[25]Tsuchiya A, Sotome S, Asou Y, et al. Effects of pore size and implant volume of porous hydroxyapatite/collagen (HAp/Col) on bone formation in a rabbit bone defect model. J Med Dent Sci. 2008;55(1):91-99.

[26]Zhang H, Wang W, Chu D, et al. Preliminary study on chitosan/HAP bilayered scaffold. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008;22(11):1358-1363.

[27]Han XQ, Han XQ, Dong ZH, et al. Experimental study of tissue-engineered bone constructed with simvastatin carried by PLGA/CPC and bone marrow stromal cells. Shanghai Kou Qiang Yi Xue. 2014;23(1):7-14.

[28]Lee K, Weir MD, Lippens E, et al. Bone regeneration via novel macroporous CPC scaffolds in critical-sized cranial defects in rats. Dent Mater. 2014;30(7):e199-207.